KVUE stock icon

Kenvue
KVUE

$17.93
1.65%

Market Cap: 34.3B

 

About: Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Employees: 22,000

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 10 analysts
0
News positive %
of 11 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

180% more call options, than puts

Call options by funds: $419M | Put options by funds: $150M

19% more repeat investments, than reductions

Existing positions increased: 389 | Existing positions reduced: 328

0.08% more ownership

Funds ownership: 97.63% [Q4 2023] → 97.7% (+0.08%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 18 [Q4 2023] → 18 (+0) [Q1 2024]

0% less capital invested

Capital invested by funds: $40.2B [Q4 2023] → $40.1B (-$121M) [Q1 2024]

3% less funds holding

Funds holding: 967 [Q4 2023] → 934 (-33) [Q1 2024]

21% less first-time investments, than exits

New positions opened: 124 | Existing positions closed: 157

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$18
0%
upside
Avg. target
$21
19%
upside
High target
$24
34%
upside

10 analyst ratings

positive
40%
neutral
50%
negative
10%
JP Morgan
Andrea Teixeira
23%upside
$22
Overweight
Maintained
22 Jul 2024
Citigroup
Filippo Falorni
12%upside
$20
Neutral
Maintained
10 Jul 2024
Citigroup
Filippo Falorni
17%upside
$21
Neutral
Reinstated
28 May 2024
HSBC
Jeremy Fialko
17%upside
$21
Hold
Maintained
8 May 2024
Bernstein
Callum Elliott
0%upside
$18
Underperform
Initiated
11 Apr 2024

Financial journalist opinion

Based on 11 articles about KVUE published over the past 30 days